Maplight Therapeutics (NASDAQ:MPLT) Director Acquires $177,171.20 in Stock

Maplight Therapeutics, Inc. (NASDAQ:MPLT) Director George Pavlov bought 9,920 shares of the stock in a transaction on Friday, February 20th. The stock was purchased at an average price of $17.86 per share, for a total transaction of $177,171.20. Following the purchase, the director directly owned 25,000 shares of the company’s stock, valued at approximately $446,500. This represents a 65.78% increase in their ownership of the stock. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link.

George Pavlov also recently made the following trade(s):

• On Thursday, February 19th, George Pavlov bought 4,422 shares of Maplight Therapeutics stock. The stock was purchased at an average cost of $17.57 per share, for a total transaction of $77,694.54.
• On Wednesday, February 18th, George Pavlov acquired 10,658 shares of Maplight Therapeutics stock. The shares were purchased at an average cost of $17.48 per share, for a total transaction of $186,301.84.

Maplight Therapeutics Stock Performance

NASDAQ MPLT traded down $0.04 on Friday, reaching $17.88. The company had a trading volume of 120,504 shares, compared to its average volume of 184,868. Maplight Therapeutics, Inc. has a 52 week low of $12.24 and a 52 week high of $21.55. The company has a 50 day moving average of $17.93. The company has a market capitalization of $811.27 million and a PE ratio of -0.48.

Maplight Therapeutics (NASDAQ:MPLT) last issued its quarterly earnings results on Thursday, December 4th. The company reported ($37.18) EPS for the quarter, missing analysts’ consensus estimates of ($1.86) by ($35.32).

Institutional Investors Weigh In On Maplight Therapeutics

A number of institutional investors and hedge funds have recently added to or reduced their stakes in MPLT. Walleye Capital LLC purchased a new stake in Maplight Therapeutics in the fourth quarter worth about $205,000. MetLife Investment Management LLC purchased a new stake in shares of Maplight Therapeutics during the 4th quarter valued at $172,000. New York State Common Retirement Fund purchased a new position in Maplight Therapeutics during the 4th quarter worth $93,000. Police & Firemen s Retirement System of New Jersey acquired a new position in Maplight Therapeutics during the 4th quarter valued at about $70,000. Finally, 5AM Venture Management LLC acquired a new stake in Maplight Therapeutics in the fourth quarter worth about $16,687,000.

Analyst Ratings Changes

Several research firms recently issued reports on MPLT. Wall Street Zen raised Maplight Therapeutics from a “sell” rating to a “hold” rating in a research note on Saturday, December 20th. Jefferies Financial Group began coverage on Maplight Therapeutics in a research note on Friday, November 21st. They issued a “buy” rating and a $32.00 price target for the company. Zacks Research raised Maplight Therapeutics to a “hold” rating in a research report on Monday, November 24th. Stifel Nicolaus started coverage on Maplight Therapeutics in a report on Friday, November 21st. They set a “buy” rating and a $28.00 price target on the stock. Finally, Weiss Ratings began coverage on shares of Maplight Therapeutics in a research report on Thursday, January 22nd. They issued a “sell (e)” rating on the stock. One research analyst has rated the stock with a Strong Buy rating, three have given a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus target price of $31.00.

About Maplight Therapeutics

We are a clinical-stage biopharmaceutical company focused on improving the lives of patients suffering from debilitating central nervous system, or CNS, disorders. We were founded by globally recognized leaders in psychiatry and neuroscience research to address the lack of circuit-specific pharmacotherapies available for patients. Our discovery platform holds the potential to fill this void by identifying neural circuits causally linked to disease and targeting those circuits for therapeutic modulation.